Quince Therapeutics has relaunched under the name IRulya Therapeutics. The company will focus on clinical development of LAM-001, targeting a key pathway in pulmonary disease.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
